Quarterly Activities & Cashflow Report
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
24 October, 2024
Quarterly Activities & Appendix 4C September 2024
●
Biome records $122k of EBITDA for Q1 (Adjusted for share based payments)
○
Third consecutive quarter of positive EBITDA
●
Record cash receipts of $3.89m in Q1, up 84% vs PCP
●
Biome reports record quarterly sales revenue $4.25m, up 12% vs Q4 FY24
●
Biome maintains gross margin above 60% for Q1
●
Same-store pharmacy sales for Q1 up 68% vs PCP
●
Clinically proven cholesterol lowering product, Biome Cholesterol launched
●
Test market in Canada commenced and strategic distribution deal signed
●
As at September 30th, the company has a cash balance of $2.67m
Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the
company’) is pleased to provide its Appendix 4C and Activity Report for the quarter ended
30 September 2024.
The company is pleased to report sales revenue of $4.25m for Q1, representing a 12%
increase compared to the previous quarter (Q4 FY24). Cash receipts increased to $3.89m,
up 84% on PCP, and gross margin was maintained above 60%. This result led to a strong
start to FY25 with Q1 sales revenue representing an annualised run rate of ~$17m.
A key factor in Biome’s ongoing commercialisation success is the development of its
underlying business and same-store sales. Same-store sales in pharmacy increased by
68% in Q1 vs PCP (Q1 FY24). Additionally, Biome delivered its third quarter of positive
EBITDA, recording $122k in Q1.
In Q1, Biome released its three year strategic plan, Vision 27. With this plan, Biome laid out
its growth and development pipeline for the period and a top-line cumulative revenue
goal of between $75m and $85m (FY25-27).
The company is well funded, with cash at bank $2.67m at 30 September. Biome expects
to remain EBITDA positive over the coming periods.
Company Financial and Corporate Overview
Biome reported positive EBITDA of $122k for the September quarter, Q1. Cash at the end
of the quarter was $2.67m. The company received $1.08m from the exercise of options in
Q1.
Cash flow from operating activities for Q1 was a net outflow of $1,232,692 (previous quarter
net cash inflow of $89k). This cash outflow was the result of payments to the Managing
Director and staff for annual bonuses for reaching and exceeding FY24 sales revenue
targets and a three year management long term incentive (LTI). The three year LTI was
achieved at the close of FY24, a cumulative target for FY21-FY24 ($21m) that was exceeded
by $3.3m. The LTI was fully expensed in H1 FY24 accounts, which supported Biome
maintaining positive EBITDA for the third consecutive quarter. Following payment of the
LTI during the September quarter, Biome expects to return to being cash flow positive
and remain EBITDA positive from the current quarter onwards.
During the quarter, Biome made investments in human resources, inventory and
marketing in-line with the Vision 27 three year strategic plan. This investment was
focussed around setting up for the new market launch in Canada, supporting the
growing European business and reinforcing our Australian market position. As a result
business activities expenditure was $4.0m (excluding the Managing Director’s 3-year LTI
payment and staff annual cash bonus totalling $1.15m for Q1) vs Q4 FY24, $3.05m. Business
activities expenses consist of sales, advertising and marketing costs of $590k (an increase
of $211k from previous quarter $379k). Payments for inventory and fulfillment increased by
$609k to $1.994m (previous quarter $1.21m). Other operating costs increased by $21k to
$51k, and research and development also increased by $21k to $95k vs June 2024 quarter.
The balance of operating outflows were administration and staff costs totaling $1.432m, a
$247k increase from the previous quarter.
In Q1, the company received a record $3.89m in cash receipts from customers (Q1 FY24,
$2.11m), representing an increase of $1.78m or 84% vs PCP. At the end of Q1, the company
held $2.4m in inventory (up from $1.9m in Q4 FY24), a $500k increase, representing a
wholesale value of $6m vs $4.75m (Q4 FY24).
The company notes that in Q1, the company paid $1,181,316 to Directors of the company in
fees, salaries and superannuation payments, as follows:
●
●
Executive Director
Non-executive Directors
$1,120,000 (3 year LTI payment paid in Q1)
$61,316
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
BIOME AUSTRALIA LIMITED (BIO)
ABN
Quarter ended (“current quarter”)
51 627 364 014
SEP 2024
Consolidated statement of cash flows
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Current
quarter
$A’000
Year to date
(....3...months)
$A’000
3,888
3,888
(95)
(95)
(b) inventory & fulfilment
(1,994)
(1,994)
(c) other operating costs
(51)
(51)
(d) sales, advertising and marketing
(590)
(590)
(e) staff costs (incl annual cash bonus)
(1231)
(1,231)
(f) administration and corporate costs
(201)
(201)
(1,000)
(1,000)
(a) research and development
(g) Managing Director’s 3-year LTI
1.3
Dividends received (see note 3)
-
-
1.4
Interest received
21
21
1.5
Interest and other costs of finance
paid
(27)
(27)
1.6
Income taxes & FBT paid
–
–
1.7
Government grants including EMDG
and R&D tax rebate incentives
47
47
1.8
Other (provide details if material)
-
-
1.9
Net cash from / (used in) operating
activities
(1,233)
(1,233)
(18)
(18)
2.
Cash flows from investing
activities
2.1
Payments to acquire or for:
(a) entities
(b) businesses
(c) property, plant and
equipment
(d) investments
(e) intellectual property
(f)
other non-current
assets
(*leasehold
improvements)
2.2
Proceeds from disposal of:
(a) entities
(b) businesses
(c) property, plant and
equipment
(d) investments
(e) intellectual property
(f)
other non-current
assets
2.3
Cash flows from loans to other
entities
2.4
Dividends received (see note 3)
2.5
Other (**bank guarantee)
2.6
Net cash from / (used in)
investing activities
3.
Cash flows from financing
activities
3.1
Proceeds from issues of equity
securities (from exercise of
options)
3.2
Proceeds from issue of convertible
debt securities
3.3
Proceeds from issue of options
3.4
Transaction costs related to issues
of equity securities or convertible
debt securities
3.5
Proceeds from borrowings
3.6
Payments for lease liabilities
3.7
Transaction costs related to loans
and borrowings
3.8
Dividends paid
3.9
Other (repayments of borrowings)
3.10
Net cash from / (used in)
financing activities
(18)
(18)
1,084
1,084
(25)
(25)
(11)
(11)
1,048
1,048
4.
Net increase / (decrease) in cash
and cash equivalents for the
period
4.1
Cash and cash equivalents at
beginning of period
4.2
Net cash from / (used in)
operating activities (item 1.9
above)
2,869
2,869
(1,233)
(1,233)
4.3
Net cash from / (used in) investing
activities (item 2.6 above)
(18)
(18)
4.4
Net cash from / (used in) financing
activities (item 3.10 above)
1,048
1,048
4.5
Effect of movement in exchange
rates on cash held
0
(2)
4.6
Cash and cash equivalents at
end of period
2,666
2,666
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
5.
at the end of the quarter (as
shown in the consolidated
statement of cash flows) to the
related items in the accounts
5.1
Bank balances
2,666
2,869
5.2
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at
end of quarter (should equal
item 4.6 above)
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and
their associates included in item 1
$1,181,316
6.2
Aggregate amount of payments to related parties and
their associates included in item 2
nil
2,666
2,869
Current quarter
$A'000
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must
include a description of, and an explanation for, such payments.
The amount paid to Directors of the Company during the quarter was $1,181,316 in fees,
salaries and superannuation payments, as follows:
7.
·
Executive Director
$1,120,000
·
Non-executive Directors
$61,316
Financing facilities
Note: the term “facility’ includes
all forms of financing
arrangements available to the
entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
1,500
1,000
Add notes as necessary for an
understanding of the sources of
finance available to the entity.
7.1
Loan facilities
7.2
Credit standby arrangements
Nil
n/a
7.3
Other (please specify)
Nil
n/a
7.4
Total financing facilities
1,500
1,000
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the
lender, interest rate, maturity date and whether it is secured or unsecured. If
any additional financing facilities have been entered into or are proposed to
be entered into after quarter end, include a note providing details of those
facilities as well.
500
Biome Australia Trading Pty Ltd (“Biome Trading”) a wholly owned
subsidiary of The Company has entered into a $1.5 million secured debt
facility (“Facility”) with Tradeplus24 (TP24) for working capital purposes to
fund future growth.
The current interest rate of the Facility is 11.1384% per annum, with a portion
tied to the 30-day bank Bill Swap Rate (“BBSW”) bid rate as at midday on the
first working day of each month plus a fixed margin of 6.8%. The Facility has a
facility fee of 1.8% per annum. The Facility is repayable by 30 June 2025 and
is secured by a General Security Agreement over the whole of Biome
Trading’s assets, a first ranking priority charge over the whole of Biome
Trading’s receivables (debtor) book and a Deed of Guarantee and
Indemnity from the Company, supported by a General Security Agreement
over the whole of the assets of the Company as well as a Deed of
Subordination over intercompany loans. It is the company’s intention to seek
a renewal of this facility before the end of FY25 if required.
8.
Estimated cash available for future operating
activities
$A’000
8.1
Net cash from / (used in) operating activities (item 1.9)
(1,233)
8.2
Cash and cash equivalents at quarter end (item 4.6)
2,666
8.3
Unused finance facilities available at quarter end (item
7.5)
500
8.4
Total available funding (item 8.2 + item 8.3)
3,166
8.5
Estimated quarters of funding available (item 8.4
divided by item 8.1)
2.6
Note: if the entity has reported positive net operating cash flows in item 1.9,
answer item 8.5 as “N/A”. Otherwise, a figure for the estimated quarters of
funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following
questions:
8.6.1
Does the entity expect that it will continue to have the current level
of net operating cash flows for the time being and, if not, why not?
Answer:
n/a
8.6.2
Has the entity taken any steps, or does it propose to take any steps,
to raise further cash to fund its operations and, if so, what are those
steps and how likely does it believe that they will be successful?
Answer:
n/a
8.6.3
Does the entity expect to be able to continue its operations and to
meet its business objectives and, if so, on what basis?
Answer:
n/a
Note: where item 8.5 is less than 2 quarters, all of questions
8.6.1, 8.6.2 and 8.6.3 above must be answered.
Compliance statement
Date:
1
This statement has been prepared in accordance with accounting
standards and policies which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
22 October 2024
Authorised by: by the Board
(Name of body or officer authorising release – see note 4)
Notes
1. This quarterly cash flow report and the accompanying activity report provide a basis for
informing the market about the entity’s activities for the past quarter, how they have
been financed and the effect this has had on its cash position. An entity that wishes to
disclose additional information over and above the minimum required under the Listing
Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian
Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash
Flows apply to this report. If this quarterly cash flow report has been prepared in
accordance with other accounting standards agreed by ASX pursuant to Listing Rule
19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or
cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors,
you can insert here: “By the board”. If it has been authorised for release to the market by a
committee of your board of directors, you can insert here: “By the [name of board
committee – eg Audit and Risk Committee]”. If it has been authorised for release to the
market by a disclosure committee, you can insert here: “By the Disclosure Committee”.
5. If this report has been authorised for release to the market by your board of directors
and you wish to hold yourself out as complying with recommendation 4.2 of the ASX
Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO
that, in their opinion, the financial records of the entity have been properly maintained,
that this report complies with the appropriate accounting standards and gives a true and
fair view of the cash flows of the entity, and that their opinion has been formed on the
basis of a sound system of risk management and internal control which is operating
effectively.
Note: The Company has become aware the link in footnote 1 to the ASX Announcement
made on 19 August 2024 did not work. The Company provides the following working link:
https://content.iospress.com/download/mediterranean-journal-of-nutrition-and-metab
olism/mnm0065?id=mediterranean-journal-of-nutrition-and-metabolism%2Fmnm0065
–ENDS–
Approved for release by the Biome Australia board of directors.
Investor Hub
Biome has launched a new interactive investor hub. To view a video presentation of this
announcement, ask questions or sign up for future company updates, please visit the
investor hub via this link (https://investorhub.biomeaustralia.com/).
About Biome Australia Limited
Biome Australia develops, licenses, commercialises and markets innovative,
evidence-based live biotherapeutics (probiotics) and complementary medicines, many of
which are supported by clinical research. Biome aims to improve health outcomes and
quality of life, and make its products accessible to all.
Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with
some of the world's leading organisations in microbiome research and development,
Biome produced several unique live biotherapeutic (probiotic) products with innovative
delivery technologies that improve their stability and efficacy to create its flagship range
®
of complementary medicines: Activated Probiotics .
Supported by clinical research, including randomised double-blind placebo-controlled
trials, Activated Probiotics help prevent and support the management of various health
concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema
and IBS. Through practitioner-only distribution, Biome is committed to educating health
professionals on the newfound systemic health effects of the gut microbiota, helping
them to provide innovative, evidence-based natural medicines for the management of
some of humanity's most prevalent and chronic health concerns.
Biome also develops, licenses and distributes a scientifically formulated, organic
®
nutraceutical range, Activated Nutrients .
For more information visit: www.biomeaustralia.com
Investor Relations
Jo Power
corporate@biomeaustralia.com
(03) 9017 5800
Forward looking statements
This release may contain forward looking statements, including but not limited to projections,
guidance on future revenues, earnings, other potential synergies and estimates and the future
performance of Biome (Forward Looking Statements).
Forward Looking Statements are provided as a general guide only and should not be relied upon
as an indication or guarantee of future performance. Actual results, performance or achievements
may differ materially from those expressed or implied in such Forward Looking Statements and
any projections and assumptions on which these Forward Looking Statements are based. Such
statements may assume the success of Biome's business strategies. You are cautioned not to place
undue reliance on Forward Looking Statements.
The Forward Looking Statements are based on information available to Biome as at the date of
this release. Any Forward Looking Statements containing forward looking financial information
provided in this release is for illustrative purposes only and is not represented as being indicative of
Biome's views on its future financial condition and/or performance. The historic financial
information for the September 2021 financial quarter and revenue figures for October and
November 2021 have not been audited or reviewed by Biome's auditors. Such information should
not be taken as a guide for future performance.
Nothing in this release is a promise or representation as to the future. No representation or
warranty, express or implied, is made as to the accuracy, likelihood of achievement or
reasonableness of any Forward Looking Statements contained in this release. Except as required
by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any
additional or updated information whether as a result of a change in expectations or assumptions,
new information, future events or results or otherwise.
To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in
respect of, and makes no representation or warranty, express or implied as to the fairness,
currency, accuracy, reliability or completeness of information in this release or the accuracy,
likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or
results expressed or implied in any Forward Looking Statements) contained in, implied by, the
information in this release or any part of it, or that this release contains all material information
about Biome or which a prospective investor or purchaser may require in evaluating a possible
investment in Biome or acquisition of securities in Biome.
Investors are strongly cautioned not to place undue reliance on Forward Looking Statements,
particularly in light of the current economic climate and the significant volatility, uncertainty and
disruption caused by the Covid-19 pandemic.
Share your feedback
Discover